Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Prof Nitzan Rosenfeld

Back to Search
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot J-M, Duruisseaux M et al. ( 2024 ) . LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer . Journal of Thoracic Oncology vol. 20 , ( 4 ) 437 - 450 .
Jensen SØ, Moore DA, Surani AA, Crosbie PAJ, Rosenfeld N, Rintoul RC ( 2024 ) . Second Primary Lung Cancer—Potential Areas of Ambiguity . Journal of Thoracic Oncology vol. 19 , ( 12 ) e101 - e102 .
Kwong FLA, Kristunas C, Davenport C, Deeks J, Mallett S, Agarwal R, Kehoe S, Timmerman D et al. ( 2024 ) . Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer . International Journal of Gynecological Cancer
Jensen SØ, Moore DA, Surani AA, Crosbie PAJ, Rosenfeld N, Rintoul RC ( 2024 ) . Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivors . Journal of Thoracic Oncology vol. 19 , ( 10 ) 1415 - 1426 .
Pope B, Park G, Lau E, Belic J, Lach R, George A, McCoy P, Nguyen A et al. ( 2024 ) . Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer . European Urology vol. 85 , ( 4 ) 407 - 410 .
Crispin-Ortuzar M, Woitek R, Reinius MAV, Moore E, Beer L, Bura V, Rundo L, McCague C et al. ( 2023 ) . Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer . Nature Communications vol. 14 , ( 1 )
Santonja A, Cooper WN, Eldridge MD, Edwards PAW, Morris JA, Edwards AR, Zhao H, Heider K et al. ( 2023 ) . Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer . EMBO Molecular Medicine vol. 15 , ( 6 )
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N et al. ( 2023 ) . Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer . Nature Communications vol. 14 , ( 1 )
Sauer CM, Heider K, Belic J, Boyle SE, Hall JA, Couturier D, An A, Vijayaraghavan A et al. ( 2022 ) . Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models . EMBO Molecular Medicine vol. 14 , ( 8 )
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N et al. ( 2022 ) . Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer . Nature Communications vol. 13 , ( 1 )
Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N ( 2022 ) . The future of early cancer detection . Nature Medicine vol. 28 , ( 4 ) 666 - 677 .
Hudecova I, Smith CG, Hänsel-Hertsch R, Chilamakuri C, Morris JA, Vijayaraghavan A, Heider K, Chandrananda D et al. ( 2021 ) . Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA . Genome Research vol. 32 , ( 2 )
Wan JCM, Mughal TI, Razavi P, Dawson S-J, Moss EL, Govindan R, Tan IB, Yap Y-S et al. ( 2021 ) . Liquid biopsies for residual disease and recurrence . Med vol. 2 , ( 12 ) 1292 - 1313 .
Mouliere F, Smith CG, Heider K, Su J, van der Pol Y, Thompson M, Morris J, Wan JCM et al. ( 2021 ) . Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients . EMBO Molecular Medicine vol. 13 , ( 8 )
Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, Ruiz-Valdepenas A, Santonja A et al. ( 2020 ) . ctDNA monitoring using patient-specific sequencing and integration of variant reads . Science Translational Medicine vol. 12 , ( 548 )
Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K et al. ( 2020 ) . Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors . Genome Medicine vol. 12 , ( 1 )
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T et al. ( 2018 ) . Enhanced detection of circulating tumor DNA by fragment size analysis . Science Translational Medicine vol. 10 , ( 466 )
Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, Morris J, Watts C et al. ( 2018 ) . Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients . EMBO Molecular Medicine vol. 10 , ( 12 )
Woodhouse S, Plagnol V, Howarth K, Lensing S, Smith M, Epstein M, Madi M, Smalley S et al. ( 2018 ) . Abstract 939: Analytical validation of InVisionFirst™, a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients . Cancer Research . vol. 78 , 939 - 939 .
Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, Soo RA, Lim HL et al. ( 2018 ) . Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer . EMBO Molecular Medicine vol. 10 , ( 6 )
Patel K, Massie C, Marass F, Morris J, Lynch A, Mouliere F, Neal D, Gnanapragasam V et al. ( 2018 ) . PD56-03 DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA . Journal of Urology vol. 199 , ( 4 ) e1062 - e1063 .
Gale D, Lawson ARJ, Howarth K, Madi M, Durham B, Smalley S, Calaway J, Blais S et al. ( 2018 ) . Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA . PLOS ONE vol. 13 , ( 3 )
Plagnol V, Woodhouse S, Howarth K, Lensing S, Smith M, Epstein M, Madi M, Smalley S et al. ( 2018 ) . Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling . PLOS ONE vol. 13 , ( 3 )
Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F et al. ( 2017 ) . Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer . Scientific Reports vol. 7 , ( 1 )
Forshew T, Lawson A, Smalley S, Plagnol V, Calaway J, Blais S, Howarth K, Jones G et al. ( 2017 ) . P2.03b-093 Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories Topic: Biomarkers . Journal of Thoracic Oncology vol. 12 , ( 1 ) s992 - s993 .
Gale D, Plagnol V, Lawson A, Pugh M, Smalley S, Howarth K, Madi M, Durham B et al. ( 2016 ) . Abstract 3639: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay . Cancer Research . vol. 76 , 3639 - 3639 .
Swanton C, Soria J-C, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C et al. ( 2016 ) . Consensus on precision medicine for metastatic cancers: a report from the MAP conference . Annals of Oncology vol. 27 , ( 8 ) 1443 - 1448 .
Smalley SK, Gale D, Lawson AR, Remon-Masip J, Perez E, Pugh M, Howarth K, Touat M et al. ( 2015 ) . Abstract B7: Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform . Molecular Cancer Therapeutics vol. 14 , ( 12_Supplement_2 ) b7 - b7 .
Lawson AR, Plagnol V, Fahem A, Forshew T, Brenton JD, Gale D, Rosenfeld N ( 2015 ) . Abstract 2412: Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform . Cancer Research . vol. 75 , 2412 - 2412 .
Plagnol V, Lawson A, Forshew T, Fahem A, Brenton J, Gale D, Rosenfeld N ( 2015 ) . Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) e22057 - e22057 .
Tsui D, Wong ASC, Murtaza M, Forshew T, Soo R, Lim HL, Goh BC, Gale D et al. ( 2014 ) . 58: Proffered Paper: Noninvasive monitoring of tumour mutations and dynamics in circulating DNA of non-small cell lung cancer patients treated with EGFR inhibitors . European Journal of Cancer . vol. 50 , s14 - s15 .
Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong C-AJ et al. ( 2014 ) . Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis . Nature Genetics vol. 46 , ( 8 ) 837 - 843 .
Weaver J, Ross-Innes C, Shannon N, Lynch A, Murtaza M, Forshew T, Dunning M, Underwood T et al. ( 2014 ) . PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics . Gut . vol. 63 ,
Weaver JM, Ross-Innes C, Shannon NB, Lynch A, Forshew T, Barbera M, Ong C-AJ, Murtaza M et al. ( 2014 ) . 935 The Timing of Oncogenic Events in the Evolution of the Oesophageal Adenocarcinoma Genome and Implications for Clinical Diagnostics . Gastroenterology vol. 146 , ( 5 ) s - 161 .
Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I et al. ( 2013 ) . Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma . Genes Chromosomes and Cancer vol. 53 , ( 1 ) 38 - 51 .
Azizan EAB, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S et al. ( 2013 ) . Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension . Nature Genetics vol. 45 , ( 9 ) 1055 - 1060 .
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E et al. ( 2013 ) . Mutant p53 Prolongs NF-kB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer . Cancer Cell vol. 24 , ( 2 )
Weaver J, Shannon N, Ross-Innes C, Lynch A, Forshew T, Barbera M, Ong C-A, Lao-Sirieix P et al. ( 2013 ) . OC-066 The Cancer Research UK (Cruk) Funded ICGC Oesophageal Adenocarcinoma Project: MRC Research Centre and Cruk Cambridge Research Institute . Gut . vol. 62 ,
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E et al. ( 2013 ) . Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer . Cancer Cell vol. 23 , ( 5 ) 634 - 646 .
Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin S-F et al. ( 2013 ) . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA . Nature vol. 497 , ( 7447 ) 108 - 112 .
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D et al. ( 2013 ) . Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer . New England Journal of Medicine vol. 368 , ( 13 ) 1199 - 1209 .
Dawson S, Tsui D, Murtaza M, Biggs H, Chin S, Gale D, Forshew T, Wallis M et al. ( 2012 ) . 171O Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells . Annals of Oncology vol. 23 ,
Dawson S, Tsui D, Murtaza M, Biggs H, Chin SF, Gale D, Forshew T, Wallis M et al. ( 2012 ) . 876 Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells . European Journal of Cancer . vol. 48 , s211 - s212 .
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, Dawson S-J, Piskorz AM et al. ( 2012 ) . Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA . Science Translational Medicine vol. 4 , ( 136 )
Back to Search